Loading clinical trials...
Loading clinical trials...
LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors
Conditions
Interventions
Zilovertamab vedotin
Locations
67
United States
Children's Hospital Los Angeles ( Site 1006)
Los Angeles, California, United States
Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016)
Aurora, Colorado, United States
Yale New Haven Hospital ( Site 1012)
New Haven, Connecticut, United States
Johns Hopkins All Children's Hospital ( Site 1025)
St. Petersburg, Florida, United States
University of Iowa-Holden Comprehensive Cancer Center ( Site 1017)
Iowa City, Iowa, United States
Dana-Farber Cancer Institute ( Site 1013)
Boston, Massachusetts, United States
Start Date
August 16, 2024
Primary Completion Date
March 31, 2029
Completion Date
March 31, 2029
Last Updated
April 13, 2026
NCT05272384
NCT07523555
NCT07223021
NCT05674175
NCT05139017
NCT01804686
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions